MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The MET signaling pathway is frequently dysregulated in cancer via mutations, amplifications, rearrangements, and overexpression.
• MET inhibitors show clinical efficacy in solid tumors, notably non-small-cell lung cancer (NSCLC).

Purpose of the Study:

• To review the frequency and clinical validation of MET alterations in various cancer types.
• To compare the efficacy of different MET-targeted therapies based on objective response rates (ORR).
• To address challenges in MET alteration detection and explore emerging technologies.

Main Methods:

• Literature review summarizing frequency of MET alterations across cancers.
• Comparative analysis of objective response rates (ORR) for various MET inhibitors.
• Discussion of challenges in detecting MET exon 14 skipping mutations and MET amplification.
• Exploration of circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) analyses.

Main Results:

• MET alterations, including exon 14 skipping, amplification, and overexpression, are common in diverse cancers.
• Clinical trials show variable objective response rates (ORR) for MET inhibitors like crizotinib, capmatinib, and tepotinib.
• Inconsistencies exist in MET alteration detection methods and cut-off values across studies.
• Emerging technologies like ctDNA and CTC analyses show promise for improved detection and response prediction.

Conclusions:

• Standardized detection methods for MET alterations are crucial for optimizing targeted therapy efficacy.
• ctDNA and CTC analyses offer potential for non-invasive detection, treatment response prediction, and resistance mechanism identification.
• Further research is needed to refine detection strategies and improve patient outcomes in MET-targeted cancer therapy.